HomeQuestion
Is there any data to support SLNB instead of ALND in patients with clinically N2-3 breast cancer after neoadjuvant chemotherapy?
3
1 Answers
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network
The sentina trial and acsog trial had Predominant N1 disease and negative predictive value Of SNLN is not known for N2 or N3 disease